Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 30, 2014

View Archived Issues

Novel monoclonal antibodies presented by the University of Texas System

Cancer Research UK launches trial of antibody for treatment of lymphoma

Novel PDE4 inhibitor appears to have limited emetic potential

Morphosys provides overview of development pipeline

Gilead Sciences details outlook for 2014

Genfit reports new preclinical data on anticancer effects of GFT-505

Viralytics begins phase I trial of Cavatak in solid tumors

Nimbus Discovery patents novel IRAK-4 inhibitors

Pfizer recaps recent pipeline highlights

Chiesi Farmaceutici discloses new neutrophil elastase inhibitors

FDA clears path for smoking cessation trial of INV-102

Ares Trading, a subsidiary of Merck Serono, patents new IRAK-4 inhibitors

Researchers at ViiV Healthcare disclose novel agents for HIV infection

Quest PharmaTech to conduct phase II trial of oregovomab combined with Hiltonol

Roche prepares new agents for RSV infection

PCI Biotech gives update on ENHANCE study

VA-694 inhibits COX-2, releases nitric oxide and demonstrates beneficial cardiovascular effects

Omeros reports data from phase IIa OMS-824 trial

OPS-202 receives EMA orphan drug designation for management of neuroendocrine tumors

KaloBios' phase II study of KB-003 in severe asthma misses primary endpoint

Seikagaku files for Japanese approval of SI-6603 for treatment of lumbar disc herniation

Biogen and UCB sign exclusive agreements to commercialize therapies for MS and hemophilia in Asia

Mesoblast reports positive outcomes from phase II trial on back pain

Cell Therapeutics reports initiation of phase II trial of pacritinib in patients with AML

Michael J. Fox Foundation provides overview of development conducted under its Partnering Program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...